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Summary
Introduction: Sickle cell disease is a public health problem. The WHO has recommended that
global management be implemented to reduce mortality and morbidity. Since no comprehensive
care programme for bone and joint complications exists, the Caribbean Sickle Cell Disease
Center added orthopaedic consultation to screen for and monitor these complications in 1992.
Hypothesis: Comprehensive medical and surgical care of patients with sickle cell disease will
reduce the complications and disability associated with this disease.
Populations and methods: Two populations were compared to evaluate the impact of compre-
hensive disease management on the occurrence of avascular necrosis (AVN) of the femoral head
(femoral head AVN). The case-control series, [E-1994], included 115 patients (58 SS and 57 S)
without orthopaedic monitoring and was evaluated retrospectively. The other patient series,
[E-2008], included 215 patients (94 SS and 121 SC) with systematic orthopaedic care and was
followed prospectively. Age, gender, duration of follow-up, haemoglobin levels, genotype, pain
before treatment, associated humerus AVN and leg ulcers were analysed.
∗ Corresponding author. Tel.: +05 908 9140; fax: +05 908 9744.
E-mail addresses: martin.mukisi@chu-guadeloupe.fr, martin.mukisi@gmail.com (M. Mukisi-Mukaza).
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Results: Femoral head AVN occurred in young adult patients (35.3± 4 years for [E-1994] and
29± 3.4 years for [E-2008]). Only elevated haemoglobin levels were associated with the occur-
rence of femoral head AVN, which suggests that increased blood viscosity contributes to the
condition ([E-1994], P < 0.0001; [E-2008], P = 0.001). Treatment in [E-2008] patients reduced the
number of femoral head AVN cases from 36.5% in [E-1994] to 14.4% in [E-2008] (P < 0.0001).
Discussion: The prevention and management of femoral head AVN must include medical treat-
ment of the disease to reduce the occurrence of painful vaso-occlusive crises, which are known
to trigger femoral head AVN. The effectiveness of this programme hinged on identifying risk
factors and using simple approaches (hydration, pain medication, rest and crutches) to manage
painful joint crises before femoral head AVN appeared. These approaches could be implemented
in disadvantaged countries where sickle cell disease is prevalent.
Conclusion: By knowing the risk factors, symptomatic patients who are at risk for femoral head
AVN can be identiﬁed and additional evaluations can be performed early on in cases of hip pain.
Level of evidence: Level III, case-control study.
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Introduction
Sickle cell disease (SS homozygote and SC double heterozy-
gote, Punjab SD, S thalassemia) is a signiﬁcant public
health problem in Africa, the Mediterranean and the West
Indies, which now has spread throughout the world [1]. In
Europe, in addition to thalassemia, the S gene has been
detected in African and West Indian immigrant populations
at a frequency of 2.4% in Brussels, 2.1% in London and 2.4% in
Paris [2—6]. Paradoxically, in Northern European countries,
haemoglobin diseases (thalassemia and sickle cell disease)
are considered to be rare genetic diseases, but they have
become a public health concern [7]. Migration explains the
presence of the S gene in various regions of the world
(Table 1). This hereditary haemoglobin disease was declared
as a public health priority in 1990 by Guadeloupe, in 2005
by the Union of African States, in 2006 by the WHO and in
2008 by the United Nations [8—11]. The variability in clinical
signs and complications make this disease challenging. Clin-
ical symptoms can be severe in some patients and limited in
others. Recommended management consists of:
• primary prevention: use of targeted information to reduce
the number of births to parents who are carriers;
• secondary prevention: anticipate and reduce the occur-
rence of complications by screening new-borns and
monitoring them after birth (evaluation of time without
clinical symptoms or baseline, antibacterial prophylaxis,
vaccination, patient and parent education);
Table 1 Presence of the S gene in various regions of the
world.
Region % Region %
Cuba 5 Saudi Arabia 5—25
Puerto Rico 5 Greece 8—27
Jamaica 10 Brazil 7—10
Italy (south) 10 India 9—38
Venezuela 11 Caribbean Islands 10—12
Curacao 12 Panama 12—14
Surinam 15 Africa 15—40
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tertiary prevention: screening and treatment of
complications [8—11].
Bone and joint complications are common in sickle cell
isease (bone infarction, bone infection, necrosis) in about
1% of patients. Bone infection is the most common compli-
ation, especially in African countries [12]. Among potential
septic joint complications, the most common and the most
isabling is avascular necrosis of the femoral head (femoral
ead AVN). Management is difﬁcult [13—16].
Since 1984, the systematic screening of new-borns and
arly medical care of children with sickle cell disease have
esulted in very few bone and joint infections in Guade-
oupe. However management of aseptic necrosis has not
et been set out in a systematic manner [17]. In 1992, the
aribbean Sickle Cell Disease Centre in Guadeloupe invited
s to develop a comprehensive management programme for
ip necrosis that included the following elements [18—23]:
prevention of humerus and femoral head avascular necro-
sis through patient education about the early signs of hip
or shoulder involvement;
clinical examination after every vaso-occlusive crisis or
child-birth episode and resting a hip that is painful (pain
medication, use of crutches and canes to unload painful
hip);
prevention of sequela through conservative surgical treat-
ment (drilling, osteotomy).
We performed a descriptive, comparative study to assess
he risk factors for femoral head AVN and evaluate the
ffectiveness of a comprehensive management programme
medical and orthopaedic) on the occurrence of femoral
ead AVN in patients with sickle cell disease. The study com-
rised two series of patients with sickle cell disease who
ere at least 16 years of age. The ﬁrst series, [E-1994],
ncluded patients identiﬁed as having sickle cell disease
tarting in 1984 at the Pointe-à-Pitre Hospital, before the
aribbean Sickle Cell Disease Centre opened. These patients
ere not monitored regularly, thus their data were col-ected retrospectively. The second series, [E-2008], included
ll the patients with sickle cell disease who were identi-
ed at the Caribbean Sickle Cell Disease Centre between
995 and 2008, provided informed consent and did not have
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Pain related to femoral head AVN was present in 50% of
patients, both SS and SC, in the [E-1994] series. In the [E-
2008] series, pain was present in 42% of cases, but not in 58%
of cases. There were no differences between the two periods
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history of femoral head AVN. These patients were fol-
owed prospectively and were monitored by medical and
rthopaedic personnel.
atients and methods
atients
he [E-1994] series included 115 patients (58 SS and 57 SC;
2 men and 73 women). The [E-2008] series included 215
atients (94 SS and 121 SC; 85 men and 130 women) who
ere monitored regularly. The minimum age for inclusion
nto either series was 16 years. The evaluations consisted
f:
clinical examination of the hip and other joints at each
visit by doctors familiar with sickle cell disease man-
agement; radiographs of the hips and shoulders at the
ﬁrst visit with an orthopaedic surgeon monitoring patients
every year;
consultation after each crisis and bone imaging (radio-
graphs and MRI when humeral head or femoral head AVN
suspected);
joint unloading and anti-inﬂammatory medication in cases
of hip pain; d) parent, adolescent (not evaluated here)
and patient education to encourage them to mention any
persistent hip pain.
iagnosis of femoral head avascular necrosis
he diagnosis of femoral head AVN was based on data in
edical records, clinical examination, hip and shoulder
adiographs performed on the [E-1994] and [E-2008] series,
nd bone and joint evaluations of the hip. Radiographs and
ec-99 bone scans were performed annually or when the
atient presented with symptoms. CT scan or magnetic res-
nance imaging (MRI) was requested following an abnormal
one scan or cases of persistent pain to assist in making a
iagnosis of femoral head AVN [18,24]. Other joints (shoul-
er, knee, ankle, lumbar spine) were evaluated and imaging
odalities requested in cases of presenting symptoms, pain,
nd reduced range of motion [18,25—28].
ariables evaluated
ata were collected from all the patient in both series
or the following variables: patient age at ﬁrst visit, age
t diagnosis of femoral head AVN, duration of monitoring,
aemoglobin levels (Hb), femoral head AVN and haemoglobin
evels, genotype, gender, pain before treatment, bilateral
ases, femoral head AVN and shoulder involvement, femoral
ead AVN and leg ulcers.
tatistical analysis
verage values were compared according to Schwartz [29],
= (MA —MB)/(SA2/NA + SB2/NB)½ where SA2 and SB2 repre-
ent the estimated variances (difference is signiﬁcant if 
1.96). The Chi2 test was used to verify the relationship
etween two characteristics in the two populations being
F
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tudied. The P-value was derived from the software ExcelTM
P < 0.05 was a signiﬁcant difference). An odds ratio (OR) was
alculated to measure the relationship between qualitative
ariables (pain, laterality, combination with leg ulcers).
esults
haracteristics of the two patient populations
he age, gender and genotype distribution were the same for
he two series (Fig. 1, Table 2). When all the genotypes were
ooled together, the average age when femoral head AVN
as diagnosed was 35.3± 1.4 for patients in the [E-1994]
eries and 29.5± 3.4 (n = 31) for patients in the [E-2008]
eries; this difference was not signiﬁcant (P = 0.6, Table 2).
For the [E-1994] series, the average haemoglobin level
as 8.9± 0.9 g/dL in SS patients and 11.4± 0.4 g/dL in
C patients (P < 0.001). For the [E-2008] series, it was
.3± 0.3 g/dL in SS patients and 11.4± 0.3 g/dL in SC
atients (P < 0.001). If the SS and SC groups are compared
ver both time periods, only the SS group had different
aemoglobin levels (P = 0.03, Table 2).
Patients in the [E-1994] series were followed for an aver-
ge of 8.7± 0.6 years (n = 115) and patients in the [E-2008]
eries were followed for 11.3± 0.7 years (n = 215). There
as a signiﬁcant difference between the [E-1994] and [E-
008] series (P < 0.01; Table 2). When all the genotypes were
ooled together, the frequency of femoral head AVN was
6.5% (42/115) for the [E-1994] series versus 14.4% (31/215)
or the [E-2008] series (P < 0.0001; Table 3).
The average haemoglobin levels were higher in patients
ho developed femoral head AVN in the [E-1994] and
E-2008] periods (P < 0.001). There were no signiﬁcant dif-
erences in haemoglobin levels in the [E-1994] and [E-2008]
eriods (Table 3). Genotype (SS or SC) did not affect the
requency of femoral head AVN occurrence in either period
Table 3). Femoral head AVN occurred less often in women
han men in the [E-1994] series (P = 0.01). In the [E-2008]
eries, AVN occurred as often in women as in men (P = 0.9;
able 3).igure 1 Patient age distribution when disease management
nitiated. Comparison between the two cohorts: [E-1994] - [E-
008].
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Table 2 Characteristics of two series, [E-1994] without monitoring and [E-2008] with monitoring.
Period [E-1994]
n = 115
[E-2008]
n = 215
P [E-1994]—[E-2008]
Men 42 (36.5%) 85 (39.5%) n/s
Women 73 (63.5%) 130 (60.5%) n/s
SS genotype 58 (50.4%) 94 (43.7%) n/s
SC genotype 57 (49.6%) 121 (56.3%) n/s
Patient age when disease
management started
(years)
30.4± 2.1 29.5± 1.36 n/s
Age when femoral head AVN
diagnosis was made (years)
35.3± 1.4 29.5± 3.4 n/s
Average haemoglobin levels
(g/dL)
SS genotype
SC genotype
8.9± 0.9
11.4± 0.4
P = 0.001
8.3± 0.3
11.4± 0.3
P = 0.001 (SS vs SC)
n/s
n/s
n/s
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Follow-up period (years) 8.7± 0.6
(P = 0.5) (Table 3). When femoral head AVN was present,
it happened bilaterally more often in the [E-1994] series
(P = 0.005) than in the [E-2008] series (P = 0.1; Table 3).
When the combination of femoral head AVN and shoul-
der involvement was assessed in both populations, we found
that shoulder involvement was signiﬁcantly associated with
femoral head AVN (P = 0.01) (Table 3). In the [E-1994] series
where the patients were not monitored, 85.7% of patients
with femoral head AVN also had leg ulcers (P < 0.0001); this
combination was present in only 16.1% of patients in the
[E-2008] series (P = 0.0002) (Table 3). Signiﬁcantly, fewer
patients in the [E-2008] series presented with leg ulcers
(Table 3).
Discussion
The two series were directly comparable because of similar
population characteristics (age, gender and genotype). Both
series had patients above 16 years of age. Femoral head AVN
secondary to sickle cell disease occurs in younger patients
than primary or idiopathic femoral head AVN (appears at an
average age of 45 years) [28,30—33]. Treatment of advanced
femoral head AVN by arthroplasty is difﬁcult and costly,
especially in Africa and developing countries [21,34—37].
There was a signiﬁcant difference in the duration of monitor-
ing between the two series (8.7± 0.6 years for [E-1994] and
11.3± 0.7 years for [E-2008]). Although the study was not
randomized, the make-up of a control group from the same
population and the lengthy follow-up with the prospective
group in theory limits the bias that could hinder interpreta-
tion of the results (lost to follow-up, incomplete records).
Blood viscosity depends on haematocrit, plasma viscosity
(carrying phase) and rheological properties of the red blood
cells [38—41]. Elevated haemoglobin or haematocrit levels
in combination with rheological problems lead to sickling
and vaso-occlusion, especially in the femoral head sinusoids.
In our study, there was a relationship between elevated
haemoglobin levels and femoral head AVN, which suggests
b
[
o
[11.3± 0.7 P < 0.01
hat vaso-occlusion and increased viscosity are determining
actors for femoral head AVN [42].
The frequency of femoral head AVN as a function of geno-
ype and gender has been debated, and varied by series
n this study. The study by Hernigou et al. [21] with 131
atients (101 SS and 30 SC) suggested that it was more com-
on in SS homozygotes (42%) than SC double heterozygotes
20%); it was also more common in women than in men.
ther studies have reported a higher occurrence in SC than
S genotypes. This no longer holds true today; the aver-
ge lifespan is similar in both groups because of improved
isease management. Gender and genotype were not risk
actors for femoral head AVN, that should be sought in all
atients [14,23,28].
In contrast to idiopathic necrosis, asymptomatic forms
f femoral head AVN were seen that could appear normal
or a long period of time. The weak relationship between
ymptoms and necrosis before treatment can be explained
y episodes of latent sickling, with little pain, that cause
one infarction in the femoral head (sclerosis often seen by
hance during the treatment of symptomatic femoral head
VN on the contralateral side) [24,43]. The lack of pain doc-
mented in this study suggests that femoral head AVN could
rogress with or without symptoms. Surgical treatment is
ot justiﬁed in these cases of asymptomatic necrosis, but
hese cases should be monitored clinically [18,43]. Necro-
is in the hip can be unilateral or bilateral. Bilateral cases
ccurred in 54% of patients in the study by Milner et al. [23].
n our study, bilateral cases were more frequently observed
n the [E-1994] series, which can be explained by the lack of
edical monitoring in the [E-1994] period. Targeted eval-
ations and appropriate care should be performed on the
ealthy contralateral hip [43].
Involvement of the epiphysis of multiple joints and bones
f an individual has been reported, with humeral head AVN
eing the most common [18,21,27,28,44—46]. Milner et al.
46] reported this in more than 50% of their patients. In
ur study, the shoulder was involved more often in the
E-2008] series than in the [E-1994] series (P = 0.01), which is
818 M. Mukisi-Mukaza et al.
Table 3 Results of comparison between the two groups: [E-1994] without monitoring and [E-2008] with monitoring.
Period [E-1994]
n = 115
[E-2008]
n = 215
OR P [E-1994]—[E-2008]
Femoral head AVN occurrence rate 42/115 (36.5%) 31/215 (14.4%) P < 0.001
Hb levels (g/dL) as a function of femoral head AVN
Femoral head AVN + 11.3± 0.5 11.1± 0.5 n/s
Femoral head AVN 9.5± 0.5
P < 0.001
10.1± 0.3
P < 0.001
n/s
Frequency relative to genotype Femoral head
AVN+
Femoral head
AVN+
SS 21 (50%) 14 (45.2%) n/s
SC 21 (50%)
P = 1
17 (54.8%)
P = 0.6
n/s
Frequency of femoral head AVN relative to gender
(M/F)
Men 21/42 (50.0%) 12/85 (14.1%) P < 0.001
Women 21/73 (28.8%)
P = 0.01
19/130 (14.6%)
n/s
P < 0.001
Pain associated with femoral head AVN before
treatment
Hip pain 21/42 (50%) 13/31 (42%) 0.73
No pain 21/42 (50%)
n/s
18/31 (58%)
n/s
n/s
Femoral head AVN laterality
Unilateral 12/42 (28%) 11/31 (55.5%)
Bilateral 30/42 (72%)
P = 0.005
20/31 (64.5%)
n/s
n/s
Femoral head AVN and shoulder involvement
Association + 16/42 (38.1%) 21/31 (67.7%) P = 0.01
Association— 26/42 (61.9%)
n/s
10/31 (32.3%)
P = 0.05
Femoral head AVN and leg ulcers
Ulcer + 36/42 (85.7%) 5/31 (16.1%) 32.2 P < 0.0001
(14.3
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P < 0.0
ttributed to the systematic monitoring during the prospec-
ive study. The epiphysis is involved because vaso-occlusion
ccurs in the terminal circulation, which is similar in the
umerus and femoral head [46—48]. Symptoms are vague
n the initial stages (pain, loss of function) [25,46]. When
emoral head AVN is present, the possibility of humeral head
VN should be systematically assessed [25,28,45,46,48].
ecrosis has been identiﬁed in knees, talus and elbows
27,49].
Starting at 10 years of age, 10 to 20% of patients will
evelop leg ulcers at one point in their lifetime [50—53].
n both series, we found that femoral head AVN was signiﬁ-
antly associated with leg ulcers. Leg ulcers are considered
o be an associated factor in the appearance of femoral head
VN [18,50—53].
The reported frequency of femoral head AVN secondary
o sickle cell disease varies between 8 and 40%. In adults,
he frequency is about 40% [21,39]. This is similar to the
requency observed in [E-1994], our non-monitored pop-
lation. Data from the prospective study with [E-2008]
llowed the prevalence of femoral head AVN of 14.4% to
e calculated from a regularly monitored population. This
requency is clearly lower than published values. The
C
B
l%) 26/31 (83.9%)
P < 0.0002
E-2008] series patients had better, earlier medical care,
articularly for vaso-occlusive crises (hydration, pain med-
cation, oxygen therapy, anaemia treatment) that reduced
he risk of vaso-occlusion in bone tissue. The reduced risk
f femoral head AVN could be attributed to the parallel
onservative orthopaedic treatment in our study (bone and
oint monitoring after every vase-occlusive crisis, special
onitoring during adolescence or after pregnancy, early
nloading of a painful hip). By comparing the [E-1994] and
E-2008] series, the frequency of femoral had AVN went from
6.5% to 14.4% (P < 0.0001). Medical treatment to stop sickle
ell disease crises on one hand and conservative orthopaedic
reatment with joint unloading on the other hand, could
xplain this signiﬁcant reduction in femoral head AVN in
ur [E-2008] series. This observation should be conﬁrmed
ith a randomized study to avoid any biases that exist
ith a case-control study where only one arm was followed
rospectively.onclusion
efore the Caribbean Sickle Cell Disease Centre in Guade-
oupe was created, a sickle cell disease patient was
ickle
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[
[Risk factors for necrosis of the femoral head in adults with s
considered ‘‘at risk’’ because of the lack of medical
monitoring. The life expectancy of these patients has
improved because of systematic screening in new-borns
and early medical management (prophylaxis using long-
term antibiotic treatment, vaccination, regular monitoring,
improvements in hygiene, use of drug treatments such as
hydroxyurea).
A relationship was found between elevated haemoglobin
levels and femoral head AVN, which suggests that high blood
viscosity, hypoxia and vaso-occlusion all have a role in its
appearance. The risk factors for femoral head AVN identiﬁed
in our study (elevated Hb, presence of leg ulcers, shoul-
der involvement) can be added to those reported in the
literature: low HbF levels, association with  thalassemia
trait, low mean corpuscular volume, proliferative retinopa-
thy. By deﬁning these factors, patients with a risk of femoral
head AVN can be identiﬁed earlier, which ensures a better
follow-up. A comparison of the two series showed that com-
prehensive care (medical and orthopaedic) was beneﬁcial
to patients in the [E-2008] series. This monitoring includes
appropriate medical treatment for vaso-occlusive crises and
conservative orthopaedic treatment for hip pain, and can
explain the reduced occurrence of femoral head AVN.
The Caribbean Sickle Cell Disease Centre protocol can be
used for tertiary prevention of bone and joint complications:
• appropriate medical treatment and prevention to reduce
vaso-occlusive crises;
• patient education on the presenting symptoms in the hip
and other joints;
• clinical examination of bones and joints performed annu-
ally and after every vaso-occlusive crisis;
• special monitoring during adolescence and after a preg-
nancy;
• early, orthopaedic or conservative surgical (drilling,
osteotomy) management when necrosis is present, to
reduce the disabling complications of femoral head AVN.
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